Efficacy and safety of tocilizumab in the treatment of acute exacerbation of interstitial lung disease (AE-ILD) with cytokine release syndrome (CRS) : a real-world study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500100331

Enrollment

Unknown

Registered

2025-04-08

Start date

2025-07-01

Completion date

Unknown

Last updated

2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute exacerbation of interstitial lung disease with cytokine release syndrome

Interventions

Tolizumab group:None

Control group:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Confirmed diagnosis of ILD; 2. Acute exacerbation or progression of dyspnea within 1 month; 3. On the basis of the original ILD manifestations, diffuse ground-glass opacities or consolidation of both lungs were newly developed in HRCT; 4. Oxygenation index =18 years; 8. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: No special exclusions for real world study

Design outcomes

Primary

Measure	Time frame
Death ending;	—

Secondary

Measure	Time frame
Oxygenation index;Blood routine;C-reactive protein;Liver and kidney function;Coagulation function;Lactate dehydrogenase;Krebs Von den Lungen-6;Cytokines;Acute Physiology and Chronic Health Evaluation II, APACHE II;Sequential Organ Failure Assessment, SOFA;Days of stay;Days of ICU stay;High flow oxygen inhalation time;Days of mechanical ventilation;Safety of tolizumab;	—

Countries

China

Contacts

Public ContactFeng Li

Shanghai Chest Hospital

lifeng741@aliyun.com+86 180 1732 1517

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026